Microdose Zepbound: What the Term Means, and What Actually Exists

Last reviewed: May 12, 2026

Last updated: September 17, 2026

Written by: Jay Hastings, CEO of PlexusDx, and Jayden Lee, PharmD, EMBA, PlexusDx Medical Director

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Director, with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on Peptides & GLP-1. Browse all Peptides & GLP-1 education

“Microdose Zepbound” is a common search, and the honest answer starts with a correction. Zepbound® does not come in a microdose. This article explains what Zepbound® is, what its label allows, what people usually mean by the phrase, and how that differs from the compounded tirzepatide PlexusDx studied. Microdosing is not a medical term. In the PlexusDx study it meant a total weekly dose of 1 or 2 mg of injectable tirzepatide, below the usual 2.5 mg starting dose.

What Zepbound® is

Zepbound® is Eli Lilly and Company’s FDA-approved brand of tirzepatide. Per its label it is approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, and for obstructive sleep apnea in adults with obesity. The label starts at 2.5 mg once a week for four weeks, then 5 mg, then up in 2.5 mg steps as needed to a maximum of 15 mg a week. It is sold as single-dose pens and, in some strengths, single-dose vials. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PlexusDx is not affiliated with or endorsed by Eli Lilly and Company.

Is there a microdose Zepbound®?

No. The lowest labeled dose is 2.5 mg, and the label describes it as a starting dose to help the body adjust, not a treatment dose. A pen delivers one fixed amount. The label does not describe doses below 2.5 mg, and it does not describe splitting a dose across days. Anything below 2.5 mg is off the label, and it is not Zepbound®.

What people usually mean

In practice the phrase points to one of two things. The first is staying at the 2.5 mg starting dose for longer than the label’s four weeks. That is still the FDA-approved product; whether and how long to stay there is a prescriber’s decision. The second is compounded tirzepatide at a smaller weekly total, such as 1 or 2 mg. That is the same molecule, prepared by state-licensed compounding pharmacies operating in FDA-registered facilities, only when a licensed prescriber writes for it. Compounded medication is not an FDA-approved product and is not Zepbound®.

Do not try to make a microdose yourself by drawing part of a pen or vial. The labeled products are single-dose. Changing how much you take, or how often, is a decision for your prescriber, not a workaround.

What PlexusDx studied, and what it did not

PlexusDx looked back at records of 60 adults who started compounded injectable tirzepatide with vitamin B12 at a total weekly dose of 1 to 2 mg through its care program. It did not study Zepbound®, and its results say nothing about the brand product at any dose. The numbers, with group sizes, time windows and the number of people who did not lose weight, are in microdose tirzepatide results at 3, 7 and 9 weeks. What the word microdose meant in that study is in what is a microdose of tirzepatide.

Who decides

A licensed prescriber, every time. In the PlexusDx program, an independent network of U.S.-licensed clinicians through a state-licensed telehealth platform reviews your intake and decides whether to prescribe, what weekly total, and how to follow you. If you take Zepbound® now and want a lower dose or a slower pace, ask the prescriber who wrote for it. If you are curious about a compounded low start, see who a microdose start is for.

About the PlexusDx study

A retrospective, single-organization observational study of adults documented as new to GLP-1 medicines with BMI ≥27 kg/m²; no comparison group; self-reported weights; not a clinical trial; preprint not yet peer reviewed. The records came from the commercial care program that PlexusDx operates. Care was delivered by an independent network of U.S.-licensed clinicians through a state-licensed telehealth platform. The medication was compounded injectable tirzepatide with vitamin B12 at a total weekly dose of 1 to 2 mg, prepared by state-licensed compounding pharmacies operating in FDA-registered facilities. The study was written by Jay Hastings (PlexusDx CEO) and Jayden Lee, PharmD, EMBA (PlexusDx Medical Director). See the PlexusDx microdose tirzepatide study (60 patients, 2026).

The authors’ conclusion, in their words: “These hypothesis-generating observations support prospective comparative study, not conclusions about causality, equivalent dosing, or long-term safety.” The full preprint is on medRxiv: Weight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weekly (doi:10.64898/2026.09.15.26363172; posted September 17, 2026; CC BY 4.0). It has not yet been peer reviewed.

Where PlexusDx fits

PlexusDx offers compounded tirzepatide through its Weight Management Protocols, including the entry-tier Microdose GLP-1 Protocol. You fill out a short intake. A licensed clinician reviews it and decides what, if anything, fits you. The study described here looked back at records. It is not a promise of any result.

This article is educational. PlexusDx offers compounded tirzepatide through its Weight Management Protocols. The GLP-1 & Peptide Pathways Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol. Compounded tirzepatide is not an FDA-approved drug product. It is prepared by state-licensed compounding pharmacies under federal compounding rules and is not the same as Zepbound® or Mounjaro®. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PlexusDx is not affiliated with or endorsed by Eli Lilly and Company.

Frequently Asked Questions

Can you microdose Zepbound?

Not as a product. Zepbound® comes in fixed single doses starting at 2.5 mg a week, and its label does not describe lower doses or split dosing. What people call microdosing is either staying at 2.5 mg longer under a prescriber, or compounded tirzepatide at a smaller amount, which is not Zepbound®.

Is there a 1 mg or 2 mg Zepbound pen?

No. The labeled strengths run from 2.5 mg to 15 mg, each as a single fixed dose. Amounts below 2.5 mg exist only as compounded tirzepatide, prepared by a state-licensed compounding pharmacy when a licensed prescriber orders it. Compounded medication is not an FDA-approved drug product.

Is compounded microdose tirzepatide the same as Zepbound?

No. It is the same active ingredient at a different amount, prepared by a compounding pharmacy rather than manufactured by Eli Lilly and Company. It is not FDA-approved, has not been through the trials that supported Zepbound®, and should not be described as equivalent. Zepbound® is a registered trademark of Eli Lilly and Company.

Did the PlexusDx study use Zepbound?

No. The study looked back at 60 adults who started compounded injectable tirzepatide with vitamin B12 at a total weekly dose of 1 to 2 mg through the PlexusDx care program. It says nothing about Zepbound® at any dose, and it should not be read as a comparison with the brand product.

Can I just stay on 2.5 mg of Zepbound?

That is a question for the prescriber who wrote for it. The label treats 2.5 mg as a four-week starting dose, not a treatment dose, so staying there longer is a clinical decision made for you, weighing your goals, side effects and history. This article does not tell you what to do.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.